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N-(Un)substituted quinolone-3-carbaldehydes 1a–h and (Un)substituted benzofuran-3(2H)-ones
2a–c in the presence of 10 mol% NaOH in ethanol using a microwave irradiation method. All
the aurone derivatives were screened for in vitro antimicrobial activity against a representative panel
of bacterial and fungal pathogens using a broth microdilution method. The majority of the synthe-
sized compounds elicited more or equipotent inhibitory action against all the tested bacterial and
fungal strains. In vitro antioxidant activity was evaluated by the Ferric Reducing Antioxidant
Power (FRAP) method. Compounds 3k and 3u displayed the highest antioxidant potential.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Aurones are less studied subclass of ﬂavonoids and found
rarely in nature. Some naturally occurring aurones are mari-
timetin, sulfuretin and aureusidin which possess various
hydroxylation patterns (Romussi and Pagani, 1970; Junior
et al., 2008; Mohan and Joshi, 1989) (Fig. 1). Except those
found in nature, aurones are a fertile source of medicinally
important molecules possessing a wide spectrum of biological
activities like antioxidant (Detsi et al., 2009), insect antifeedant
(Morimoto et al., 2007), anticancer (Huang et al., 2007), anti-
bacterial and anti-inﬂammatory (Bandgar et al., 2010). More-
over, the biological activities of aurones strongly depend onthe number of hydroxyl groups present on Ring C (Dong
et al., 2009; Lee et al., 2010).
On the other hand, quinolone is a core pharmacophore in
the development of different biologically potent derivatives
which found to possess various activities such as, anti-HIV
(Gupta and Madan, 2012), antitumor (Li et al., 2006), anti-
anaerobe (Schaumann and Rodloff, 2007), antibacterial
(Sharma et al., 2011), anti-inﬂammatory and analgesic
(Filippelli, 2010). Further, it has been established that the pres-
ence of an allyl group of heterocyclic nitrogen improves anti-
microbial effectiveness and plays an important role in the
development of new antimicrobial drugs (Praveen et al.,
2011). Therefore, we selected the allyl group as a substituent
at the nitrogen of the quinolone moiety.
The conventional method for the synthesis of aurones espe-
cially by using hydroxy/dihydroxy benzofuran-3(2H)-one
encountered some problems such as, masking of OH groups,
lengthy reaction time and poor yield due to side reaction
(Detsi et al., 2009; Shin et al., 2011). Consequently, to over-
come these drawbacks, the microwave-assisted organic synthe-
sis (MAOS) approach was adopted for the synthesis of titlenalogs.
Figure 1 Structurally diverse aurones.
2 H.H. Jardosh, M.P. Patelcompounds which improved selectivity of the reaction, short-
ened reaction time and made avoidable to prevent OH groups
and gave a better yield.
Over the past few years, the development toward the con-
struction of the efﬁcient aurone scaffolds with appropriate bio-
logical activity by modifying or replacing the benzene ring with
N-(Un)substituted indoles and different spacers have been
made (Wallez et al., 2002; Gerby et al., 2007; Bursavicha
et al., 2010; Haudecoeur et al., 2011) (Fig. 1). In the radiance
of the above mentioned facts and as a prolongation of our
investigation on the synthesis of biologically active heterocy-
clic compounds (Mungra et al., 2011; Thumar and Patel,
2011; Jardosh and Patel, 2011, 2012a,b; Sangani et al., 2012;
Makawana et al., 2012; Shah et al., 2012), we were provoked
to design and synthesize new quinolone based aurone analogs
by using molecular hybridization approach and evaluate them
as antimicrobials and antioxidants.
2. Experimental
2.1. General
Required acetic acid, hydrochloric acid, potassium carbonate,
sodium acetate, N,N-dimethyl formamide, chloroform and
methanol were procured from Merck, Darmstadt, Germany.
Sodium hydroxide, zinc chloride, diethyl ether, resorcinol
and phloroglucinol were obtained from S. D. Fine Chem
Ltd., Vadodara, Gujarat, India. Allyl bromide, benzofuran-
3(2H)-one and chloroacetonitrile were purchased from
Sigma–Aldrich. Organic solvents were puriﬁed by standard
methods (Furniss et al., 2004) and stored over molecular sieves
and were used with further puriﬁcation. The microwave
assisted reactions are conducted in a ‘‘RAGA’s Modiﬁed Elec-
tromagnetic Microwave System’’ whereby microwaves arePlease cite this article in press as: Jardosh, H.H., Patel, M.P. Antimicrobia
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adjustable output power levels i.e., 10 levels from 140 to 700
Watts and with an individual sensor for temperature control
(ﬁber optic is used as an individual sensor for temperature con-
trol) with the attachment of the reﬂux condenser with constant
stirring (thus avoiding the risk of high pressure development).
Melting points of all the title compounds were determined by
the open tube capillary method (using silicon oil 350 cst) and
are uncorrected. All reactions were monitored by thin-layer
chromatography (TLC, on aluminum plates coated with silica
gel 60F254, 0.25 mm thickness, Merck) carried out on ﬂuores-
cent coated plates and detection of the components was made
by exposure to iodine vapors or UV light. Elemental analysis
(% C, H, N) was carried out by a Perkin–Elmer 2400 series-
II elemental analyzer (Perkin–Elmer, USA) and all compounds
are within ±0.4% of theory speciﬁed. The IR spectra were
recorded on a Perkin–Elmer Spectrum GX FT-IR Spectropho-
tometer (Perkin–Elmer, USA) using potassium bromide pellets
in the range of 4000–400 cm1 and frequencies of only charac-
teristic peaks are expressed in cm1. 1H NMR and 13C NMR
spectra were recorded in DMSO-d6 on a Bruker Avance 400F
(MHz) spectrometer (Bruker Scientiﬁc Corporation Ltd., Swit-
zerland) using TMS as an internal standard at 400 MHz and
100 MHz respectively. Chemical shifts are reported in parts
per million (ppm). Mass spectra were scanned on a Shimadzu
LCMS 2010 spectrometer. For antioxidant activity, UV spec-
tra were recorded on a Shimadzu Type 160-A spectrometer.
2.2. General procedure for the synthesis of compounds 1a–h
Compounds 2-oxo-1,2-dihydroquinoline-3-carbaldehydes 1a–d
and 1-allyl-2-oxo-1,2-dihydroquinoline-3-carbaldehydes 1e–h
were prepared according to the literature method (Srivastava
and Singh, 2005).l and antioxidant evaluation of new quinolone based aurone analogs.
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Quinolone based aurone analogs 32.3. General procedure for the synthesis of compounds 2a–c
Compound benzofuran-3(2H)-one 2a was purchased from
sigma aldrich. Compounds 6-hydroxybenzofuran-3(2H)-one
2b and 4,6-dihydroxybenzofuran-3(2H)-one 2c were prepared
according to the literature method (Shriner and Grosser,
1942; Horning and Reisner, 1948).
2.4. General procedure for the synthesis of compounds 3a–x
In a 50 mL round-bottom ﬂask, N-(Un)substituted quinolone-3-
carbaldehydes 1a–h (3 mmol), (Un)substituted benzofuran-
3(2H)-ones 2a–c (3 mmol), 10 mol% NaOH and 10 mL ethanol
were taken and thoroughly mixed and irradiated in a micro-
wave oven at 280 W (40% of output power) for 240 s. After
the completion of the reaction (checked by TLC; eluent, chlo-
roform:methanol::9:1), the solution was cooled to room tem-
perature, the solid separated was ﬁltered, washed well with
R-spirit (10 ml), dried and recrystallized from chloroform–
methanol (1:1) to get pure solid sample 3a–x. Physical, analyt-
ical and spectroscopic characterization data of the compounds
3a–x are given hereafter.
2.4.1. (Z)-3-((3-Oxobenzofuran-2(3H)-ylidene)methyl)
quinolin-2(1H)-one (3a)
Yield: 78%; m.p.: 226–228 C; IR (KBr, m, cm1): 3067 (ArC-
H str.), 1693, 1602 (C‚O str.); 1H NMR (DMSO-d6) dH
(ppm): 6.87 (s, 1H, oleﬁnic H), 7.24 (t, J1 = 8.0 Hz,
J2 = 8.0 Hz, 1H, H5), 7.30 (t, J1 = 7.2 Hz, J2 = 7.6 Hz, 1H,
H60), 7.35 (d, J= 8.4 Hz, 1H, H7), 7.46 (d, J= 8.4 Hz, 1H,
H70), 7.59 (d, J= 8.4 Hz, 1H, H80), 7.67 (t, J1 = 8.0 Hz,
J2 = 8.0 Hz, 1H, H6), 7.83 (d, J= 8.4 Hz, 1H, H4), 7.92 (d,
J= 7.2 Hz, 1H, H50), 8.79 (s, 1H, H40), 12.02 (s, 1H, NH);
13C NMR (DMSO-d6) dC (ppm): 109.26, 113.92, 117.10,
120.55, 120.96, 123.85, 125.82, 126.61, 129.24, 130.60, 132.20,
134.78, 137.03, 138.20, 152.05, 165.25 (16C, Ar-C + oleﬁnic
C‚C), 168.42 (C‚O), 181.57 (C‚O); MS (m/z): 290.4
[M+1]+; Anal. Calcd for C18H11NO3 (289.28 g/mol): C,
74.73; H, 3.83; N, 4.84; Found: C, 74.87; H, 4.08; N, 4.51.
2.4.2. (Z)-6-Methyl-3-((3-oxobenzofuran-2(3H)-ylidene)
methyl)quinolin-2(1H)-one (3b)
Yield: 75%; m.p.: 234–236 C; IR (KBr, m, cm1): 3067 (ArC-
H str.), 1693, 1597 (C‚O str.); 1H NMR (DMSO-d6) dH
(ppm): 2.38 (s, 3H, CH3), 6.85 (s, 1H, oleﬁnic H), 7.23 (t,
J1 = 8.0 Hz, J2 = 8.0 Hz, 1H, H5), 7.36 (d, J= 8.4 Hz, 1H,
H7), 7.47 (d, J= 8.4 Hz, 1H, H70), 7.61 (d, J= 8.4 Hz, 1H,
H80), 7.69 (t, J1 = 8.0 Hz, J2 = 8.0 Hz, 1H, H6), 7.76 (d,
J= 8.4 Hz, 1H, H4), 7.85 (s, 1H, H50), 8.60 (s, 1H, H40),
12.01 (s, 1H, NH); 13C NMR (DMSO-d6) dC (ppm): 21.69
(CH3), 108.71, 114.06, 117.16, 120.57, 121.01, 123.84, 125.80,
126.63, 129.24, 130.63, 132.21, 134.71, 137.04, 138.25, 152.07,
165.28 (16C, Ar-C + oleﬁnic C‚C), 168.38 (C‚O), 181.51
(C‚O); MS (m/z): 304.2 [M+1]+; Anal. Calcd for
C19H13NO3 (303.31 g/mol): C, 75.24; H, 4.32; N, 4.62; Found:
C, 74.98; H, 4.66; N, 4.88.
2.4.3. (Z)-6-Methoxy-3-((3-oxobenzofuran-2(3H)-ylidene)
methyl)quinolin-2(1H)-one (3c)
Yield: 71%; m.p.: 241–243 C; IR (KBr, m, cm1): 3082 (ArC-
H str.), 1690, 1616 (C‚O str.); 1H NMR (DMSO-d6) dHPlease cite this article in press as: Jardosh, H.H., Patel, M.P. Antimicrobia
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J1 = 8.0 Hz, J2 = 8.0 Hz, 1H, H5), 7.32 (d, J= 8.4 Hz, 1H,
H7), 7.43 (d, J= 8.4 Hz, 1H, H70), 7.58 (d, J= 8.4 Hz, 1H,
H80), 7.65 (t, J1 = 8.0 Hz, J2 = 8.0 Hz, 1H, H6), 7.73 (d,
J= 8.4 Hz, 1H, H4), 7.83 (s, 1H, H50), 8.62 (s, 1H, H40),
12.03 (s, 1H, NH); 13C NMR (DMSO-d6) dC (ppm): 55.41
(OCH3), 108.66, 113.97, 117.12, 120.51, 120.98, 123.81,
125.87, 126.57, 129.26, 130.62, 132.21, 134.73, 137.08, 138.24,
152.11, 165.28 (16C, Ar-C + oleﬁnic C‚C), 168.37 (C‚O),
181.42 (C‚O); MS (m/z): 320.3 [M+1]+; Anal. Calcd for
C19H13NO4 (319.31 g/mol): C, 71.47; H, 4.10; N, 4.39; Found:
C, 71.32; H, 4.49; N, 4.47.
2.4.4. (Z)-6-Chloro-3-((3-oxobenzofuran-2(3H)-ylidene)
methyl)quinolin-2(1H)-one (3d)
Yield: 76%; m.p.: 261–263 C; IR (KBr, m, cm1): 3063 (ArC-
H str.), 1697, 1601 (C‚O str.); 1H NMR (DMSO-d6) dH
(ppm): 6.84 (s, 1H, oleﬁnic H), 7.24 (t, J1 = 8.0 Hz,
J2 = 8.0 Hz, 1H, H5), 7.35 (d, J= 8.4 Hz, 1H, H7), 7.46 (d,
J= 8.4 Hz, 1H, H70), 7.61 (d, J= 8.4 Hz, 1H, H80), 7.68 (t,
J1 = 8.0 Hz, J2 = 8.0 Hz, 1H, H6), 7.76 (d, J= 8.4 Hz, 1H,
H4), 7.85 (s, 1H, H50), 8.63 (s, 1H, H40), 12.05 (s, 1H, NH);
13C NMR (DMSO-d6) dC (ppm): 109.52, 114.01, 117.35,
120.62, 121.08, 123.98, 125.91, 126.82, 129.36, 130.71, 132.41,
134.85, 137.12, 138.27, 152.18, 165.37 (16C, Ar-C + oleﬁnic
C‚C), 168.51 (C‚O), 182.15 (C‚O); MS (m/z): 324.9
[M+1]+; Anal. Calcd for C18H10ClNO3 (323.73 g/mol): C,
66.78; H, 3.11; N, 4.33; Found: C, 66.61; H, 3.02; N, 4.39.
2.4.5. (Z)-3-((6-Hydroxy-3-oxobenzofuran-2(3H)-ylidene)
methyl)quinolin-2(1H)-one (3e)
Yield: 74%; m.p.: 234–236 C; IR (KBr, m, cm1): 3472 (O-H
str.), 3067 (ArC-H str.), 1697, 1601 (C‚O str.); 1H NMR
(DMSO-d6) dH (ppm): 6.73 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz,
1H, H5), 6.87 (s, 1H, oleﬁnic H), 7.09 (s, 1H, H7), 7.31 (t,
J1 = 7.2 Hz, J2 = 7.6 Hz, 1H, H60) 7.48 (d, J= 8.4 Hz, 1H,
H70), 7.57 (d, J= 8.4 Hz, 1H, H80), 7.62 (d, J= 8.8 Hz, 1H,
H4), 7.91 (d, J= 7.2 Hz, 1H, H50), 8.78 (s, 1H, H40), 11.28 (s,
1H, OH), 12.02 (s, 1H, NH); 13C NMR (DMSO-d6) dC
(ppm): 99.43, 104.04, 113.11, 114.12, 115.71, 120.60, 123.16,
123.68, 126.59, 132.34, 132.81, 139.19, 141.01, 149.46, 167.26,
168.45 (16C, Ar-C + oleﬁnic C‚C), 160.42 (C‚O), 181.51
(C‚O); MS (m/z): 306.4 [M+1]+; Anal. Calcd for
C18H11NO4 (305.28 g/mol): C, 70.82; H, 3.63; N, 4.59; Found:
C, 70.63; H, 3.95; N, 4.30.
2.4.6. (Z)-3-((6-Hydroxy-3-oxobenzofuran-2(3H)-ylidene)
methyl)-6-methylquinolin-2(1H)-one (3f)
Yield: 71%; m.p.: 240–242 C; IR (KBr, m, cm1): 3410 (O-H
str.), 3086 (ArC-H str.), 1693, 1593 (C‚O str.); 1H NMR
(DMSO-d6) dH (ppm): 2.37 (s, 3H, CH3), 6.72 (dd,
J1 = 8.4 Hz, J2 = 1.6 Hz, 1H, H5), 6.84 (s, 1H, oleﬁnic H),
7.04 (s, 1H, H7), 7.22 (d, J= 8.4 Hz, 1H, H70), 7.37 (d,
J= 8.4 Hz, 1H, H80), 7.62 (d, J= 8.4 Hz, 1H, H4), 7.67 (s,
1H, H50), 8.69 (s, 1H, H40), 11.29 (br s, 1H, OH), 12.01 (s,
1H, NH); 13C NMR (DMSO-d6) dC (ppm): 20.80 (CH3),
99.31, 103.58, 113.15, 113.71, 115.56, 119.78, 124.43, 126.55,
128.84, 131.88, 133.42, 137.15, 141.31, 149.20, 167.17, 168.35
(16C, Ar-C + oleﬁnic C‚C), 161.18 (C‚O), 181.55 (C‚O);
MS (m/z): 320.2 [M+1]+; Anal. Calcd for C19H13NO4l and antioxidant evaluation of new quinolone based aurone analogs.
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4.02; N, 4.00.
2.4.7. (Z)-3-((6-Hydroxy-3-oxobenzofuran-2(3H)-ylidene)
methyl)-6-methoxyquinolin-2(1H)-one (3g)
Yield: 72%; m.p.: 251–253 C; IR (KBr, m, cm1): 3448 (O-H
str.), 3063 (ArC-H str.), 1690, 1597 (C‚O str.); 1H NMR
(DMSO-d6) dH (ppm): 3.75 (s, 3H, OCH3), 6.70 (dd,
J1 = 8.4 Hz, J2 = 1.6 Hz, 1H, H5), 6.81 (s, 1H, oleﬁnic H),
7.01 (s, 1H, H7), 7.20 (d, J= 8.4 Hz, 1H, H70), 7.38 (d,
J= 8.4 Hz, 1H, H80), 7.61 (d, J= 8.4 Hz, 1H, H4), 7.69 (s,
1H, H50), 8.62 (s, 1H, H40), 11.18 (br s, 1H, OH), 11.98 (s,
1H, NH); 13C NMR (DMSO-d6) dC (ppm): 55.62 (OCH3),
99.36, 103.97, 113.17, 114.08, 115.65, 120.62, 123.10, 123.61,
126.55, 132.35, 132.83, 139.21, 141.12, 149.47, 167.28, 168.45
(16C, Ar-C + oleﬁnic C‚C), 160.41 (C‚O), 181.56 (C‚O);
MS (m/z): 336.2 [M+1]+; Anal. Calcd for C19H13NO5
(335.31 g/mol): C, 68.06; H, 3.91; N, 4.18; Found: C, 67.97;
H, 3.75; N, 4.47.
2.4.8. (Z)-6-Chloro-3-((6-hydroxy-3-oxobenzofuran-2(3H)-
ylidene)methyl)quinolin-2(1H)-one (3h)
Yield: 79%; m.p.: 271–273 C; IR (KBr, m, cm1): 3441 (O-H
str.), 3082 (ArC-H str.), 1697, 1597 (C‚O str.); 1H NMR
(DMSO-d6) dH (ppm): 6.73 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz,
1H, H5), 6.85 (s, 1H, oleﬁnic H), 7.07 (s, 1H, H7), 7.25 (d,
J= 8.4 Hz, 1H, H70), 7.38 (d, J= 8.4 Hz, 1H, H80), 7.63 (d,
J= 8.4 Hz, 1H, H4), 7.68 (s, 1H, H50), 8.71 (s, 1H, H40),
11.30 (br s, 1H, OH), 12.03 (s, 1H, NH); 13C NMR (DMSO-
d6) dC (ppm): 100.02, 104.23, 113.09, 114.24, 115.64, 120.74,
123.26, 123.72, 126.67, 132.45, 132.90, 139.16, 141.13, 149.62,
167.32, 168.52 (16C, Ar-C + oleﬁnic C‚C), 160.87 (C‚O),
181.96 (C‚O); MS (m/z): 340.6 [M+1]+; Anal. Calcd for C18-
H10ClNO4 (339.73 g/mol): C, 63.64; H, 2.97; N, 4.12; Found:
C, 63.41; H, 3.33; N, 4.39.
2.4.9. (Z)-3-((4,6-Dihydroxy-3-oxobenzofuran-2(3H)-
ylidene)methyl)quinolin-2(1H)-one (3i)
Yield: 69%; m.p.: 245–247 C; IR (KBr, m, cm1): 3437 (O-H
str.), 3086 (ArC-H str.), 1690, 1593 (C‚O str.); 1H NMR
(DMSO-d6) dH (ppm): 6.10 (s, 1H, H5), 6.39 (s, 1H, oleﬁnic
H), 6.98 (s, 1H, H7), 7.26 (t, J1 = 7.2 Hz, J2 = 7.6 Hz, 1H,
H60) 7.37 (d, J= 8.4 Hz, 1H, H70), 7.48 (d, J= 8.4 Hz, 1H,
H80), 7.75 (d, J= 7.2 Hz, 1H, H50), 8.58 (s, 1H, H40), 11.01
(br s, 2H, OH), 12.09 (s, 1H, NH) ppm; 13C NMR (DMSO-
d6) dC (ppm): 92.71, 96.44, 109.23, 120.33, 123.71, 133.24,
134.07, 137.18, 139.01, 139.32, 149.54, 149.81, 157.17, 159.01,
167.91, 168.04 (16C, Ar-C + oleﬁnic C‚C), 160.38 (C‚O),
171.41 (C‚O); MS (m/z): 322.1 [M+1]+; Anal. Calcd for
C18H11NO5 (321.28 g/mol): C, 67.29; H, 3.45; N, 4.36; Found:
C, 67.60; H, 3.84; N, 4.07.
2.4.10. (Z)-3-((4,6-Dihydroxy-3-oxobenzofuran-2(3H)-
ylidene)methyl)-6-methylquinolin-2(1H)-one (3j)
Yield: 61%; m.p.: 248–250 C; IR (KBr, m, cm1): 3410 (O-H
str.), 3082 (ArC-H str.), 1682, 1628 (C‚O str.); 1H NMR
(DMSO-d6) dH (ppm): 2.37 (s, 3H, CH3), 6.08 (s, 1H, H5), 6.34
(s, 1H, oleﬁnic H), 6.96 (s, 1H, H7), 7.36 (d, J= 8.4 Hz, 1H,
H70), 7.45 (d, J= 8.4 Hz, 1H, H80), 7.73 (s, 1H, H50), 8.57 (s,Please cite this article in press as: Jardosh, H.H., Patel, M.P. Antimicrobia
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(DMSO-d6) dC (ppm): 21.69 (CH3), 92.73, 96.45, 109.22,
120.36, 123.73, 133.21, 134.02, 137.11, 139.03, 139.31, 149.58,
149.84, 157.12, 159.04, 167.95, 168.09 (16C, Ar-C + oleﬁnic
C‚C), 160.41 (C‚O), 171.32 (C‚O); MS (m/z): 336.1
[M+1]+; Anal. Calcd for C19H13NO5 (335.31 g/mol): C,
68.06; H, 3.91; N, 4.18; Found: C, 68.22; H, 4.29; N, 4.05.
2.4.11. (Z)-3-((4,6-Dihydroxy-3-oxobenzofuran-2(3H)-
ylidene)methyl)-6-methoxyquinolin-2(1H)-one (3k)
Yield: 67%; m.p.: 262–264 C; IR (KBr, m, cm1): 3437 (O-H
str.), 3067 (ArC-H str.), 1693, 1624 (C‚O str.); 1H NMR
(DMSO-d6) dH (ppm): 3.78 (s, 3H, OCH3), 6.06 (s, 1H, H5),
6.31 (s, 1H, oleﬁnic H), 6.95 (s, 1H, H7), 7.34 (d, J= 8.4 Hz,
1H, H70), 7.44 (d, J= 8.4 Hz, 1H, H80), 7.71 (s, 1H, H50),
8.54 (s, 1H, H40), 11.01 (br s, 2H, OH), 12.04 (s, 1H, NH);
13C NMR (DMSO-d6) dC (ppm): 56.12 (OCH3), 92.67, 96.41,
109.19, 120.27, 123.68, 133.21, 134.11, 137.14, 139.06, 139.36,
149.57, 149.83, 157.15, 159.04, 167.87, 168.05 (16C,
Ar-C + oleﬁnic C‚C), 160.32 (C‚O), 171.48 (C‚O); MS
(m/z): 352.1 [M+1]+; Anal. Calcd for C19H13NO6 (351.31
g/mol): C, 64.96; H, 3.73; N, 3.99; Found: C, 65.28; H, 3.50;
N, 3.72.
2.4.12. (Z)-6-Chloro-3-((4,6-dihydroxy-3-oxobenzofuran-
2(3H)-ylidene)methyl)quinolin-2(1H)-one (3l)
Yield: 68%; m.p.: 271–273 C; IR (KBr, m, cm1): 3440 (O-H
str.), 3064 (ArC-H str.), 1690, 1602 (C‚O str.); 1H NMR
(DMSO-d6) dH (ppm): 6.11 (s, 1H, H5), 6.40 (s, 1H, oleﬁnic
H), 6.99 (s, 1H, H7), 7.41 (d, J= 8.4 Hz, 1H, H70), 7.52 (d,
J= 8.4 Hz, 1H, H80), 7.81 (s, 1H, H50), 8.62 (s, 1H, H40),
11.07 (br s, 2H, OH), 12.08 (s, 1H, NH); 13C NMR (DMSO-
d6) dC (ppm): 92.81, 96.46, 109.31, 120.27, 123.66, 133.34,
134.15, 137.23, 139.12, 139.41, 149.58, 149.86, 157.23, 159.06,
167.89, 168.05 (16C, Ar-C + oleﬁnic C‚C), 160.56 (C‚O),
171.82 (C‚O); MS (m/z): 356.9 [M+1]+; Anal. Calcd for C18-
H10ClNO5 (355.73 g/mol): C, 60.77; H, 2.83; N, 3.94; Found:
C, 60.54; H, 2.44; N, 4.18.
2.4.13. (Z)-1-Allyl-3-((3-oxobenzofuran-2(3H)-ylidene)
methyl)quinolin-2(1H)-one (3m)
Yield: 79%; m.p.: 232–234 C; IR (KBr, m, cm1): 3068 (ArC-
H str.), 1692, 1603 (C‚O str.); 1H NMR (DMSO-d6) dH
(ppm): 4.96 (d, J= 4.0 Hz, 2H, NACH2A), 5.01 (d,
J= 17.2 Hz, 1H, NACH2ACH‚CHtrans), 5.14 (d,
J= 10.4 Hz, 1H, NACH2ACCH‚CHcis), 5.91 (m, 1H,
CH‚CH2), 6.86 (s, 1H, oleﬁnic H), 7.22 (t, J1 = 8.0 Hz,
J2 = 8.0 Hz, 1H, H5), 7.28 (t, J1 = 7.2 Hz, J2 = 7.6 Hz, 1H,
H60), 7.34 (d, J= 8.4 Hz, 1H, H7), 7.46 (d, J= 8.4 Hz, 1H,
H70), 7.58 (d, J= 8.4 Hz, 1H, H80), 7.68 (t, J1 = 8.0 Hz,
J2 = 8.0 Hz, 1H, H6), 7.84 (d, J= 8.4 Hz, 1H, H4), 7.91 (d,
J= 7.2 Hz, 1H, H50), 8.75 (s, 1H, H40);
13C NMR (DMSO-
d6) dC (ppm): 44.94 (allylic NACH2ACCH), 109.24, 113.84,
115.51, 117.12, 120.61, 121.14, 123.78, 125.65, 126.67, 129.34,
129.87, 131.02, 132.26, 134.72, 137.11, 138.24, 152.13, 165.36
(18C, Ar-C + oleﬁnic and allylic C‚C), 168.35 (C‚O),
181.63 (C‚O); MS (m/z): 330.2 [M+1]+; Anal. Calcd for
C21H15NO3 (329.35 g/mol): C, 76.58; H, 4.59; N, 4.25; Found:
C, 76.47; H, 4.22; N, 4.08.l and antioxidant evaluation of new quinolone based aurone analogs.
014.05.014
Quinolone based aurone analogs 52.4.14. (Z)-1-Allyl-6-methyl-3-((3-oxobenzofuran-2(3H)-
ylidene)methyl)quinolin-2(1H)-one (3n)
Yield: 75%; m.p.: 245–247 C; IR (KBr, m, cm1): 3067 (ArC-
H str.), 1697, 1597 (C‚O str.); 1H NMR (DMSO-d6) dH
(ppm): 2.32 (s, 3H, CH3), 4.97 (d, J= 4.0 Hz, 2H, NACH2A),
5.02 (d, J= 17.2 Hz, 1H, NACH2ACH‚CHtrans), 5.15 (d,
J= 10.4 Hz, 1H, NACH2ACH‚CHcis), 5.93 (m, 1H,
CH‚CH2), 6.85 (s, 1H, oleﬁnic H), 7.24 (t, J1 = 8.0 Hz,
J2 = 8.0 Hz, 1H, H5), 7.37 (d, J= 8.4 Hz, 1H, H7), 7.47 (d,
J= 8.4 Hz, 1H, H70), 7.62 (d, J= 8.4 Hz, 1H, H80), 7.68 (t,
J1 = 8.0 Hz, J2 = 8.0 Hz, 1H, H6), 7.77 (d, J= 8.4 Hz, 1H,
H4), 7.85 (s, 1H, H50), 8.60 (s, 1H, H40);
13C NMR (DMSO-
d6) dC (ppm): 21.73 (CH3), 44.95 (allylic NACH2ACH),
109.27, 113.81, 115.48, 117.16, 120.58, 121.20, 123.81, 125.72,
126.63, 129.41, 129.83, 131.07, 132.31, 134.66, 137.16, 138.31,
152.21, 165.33 (18C, Ar-C + oleﬁnic and allylic C‚C),
167.95 (C‚O), 181.45 (C‚O); MS (m/z): 344.3 [M+1]+;
Anal. Calcd for C22H17NO3 (343.38 g/mol): C, 76.95; H,
4.99; N, 4.08; Found: C, 76.61; H, 4.80; N, 4.32.
2.4.15. (Z)-1-Allyl-6-methoxy-3-((3-oxobenzofuran-2(3H)-
ylidene)methyl)quinolin-2(1H)-one (3o)
Yield: 71%; m.p.: 259–261 C; IR (KBr, m, cm1): 3063 (ArC-
H str.), 1692, 1616 (C‚O str.); 1H NMR (DMSO-d6) dH
(ppm): 3.80 (s, 3H, OCH3), 4.95 (d, J= 4.0 Hz, 2H, NACH2-
A), 5.01 (d, J= 17.2 Hz, 1H, NACH2ACH‚CHtrans), 5.12
(d, J= 10.4 Hz, 1H, NACH2ACH‚CHcis), 5.90 (m, 1H,
CH‚CH2), 6.87 (s, 1H, oleﬁnic H), 7.22 (t, J1 = 8.0 Hz,
J2 = 8.0 Hz, 1H, H5), 7.34 (d, J= 8.4 Hz, 1H, H7), 7.45 (d,
J= 8.4 Hz, 1H, H70), 7.60 (d, J= 8.4 Hz, 1H, H80), 7.67 (t,
J1 = 8.0 Hz, J2 = 8.0 Hz, 1H, H6), 7.74 (d, J= 8.4 Hz, 1H,
H4), 7.83 (s, 1H, H50), 8.62 (s, 1H, H40);
13C NMR (DMSO-
d6) dC (ppm): 55.70 (OCH3), 44.91 (allylic NACH2ACH),
109.31, 113.82, 115.43, 117.12, 120.47, 121.28, 123.84, 125.75,
126.60, 129.46, 129.84, 131.11, 132.29, 134.68, 137.21, 138.27,
152.25, 165.37 (18C, Ar-C + oleﬁnic and allylic C‚C),
167.83 (C‚O), 181.51 (C‚O); MS (m/z): 360.5 [M+1]+;
Anal. Calcd for C22H17NO4 (359.37 g/mol): C, 73.53; H,
4.77; N, 3.90; Found: C, 73.79; H, 4.82; N, 3.55.
2.4.16. (Z)-1-Allyl-6-chloro-3-((3-oxobenzofuran-2(3H)-
ylidene)methyl)quinolin-2(1H)-one (3p)
Yield: 76%; m.p.: 279–281 C; IR (KBr, m, cm1): 3082 (ArC-
H str.), 1682, 1602 (C‚O str.); 1H NMR (DMSO-d6) dH
(ppm): 4.98 (d, J= 4.0 Hz, 2H, NACH2A), 5.05 (d,
J= 17.2 Hz, 1H, NACH2ACH‚CHtrans), 5.16 (d,
J= 10.4 Hz, 1H, NACH2ACH‚CHcis), 5.95 (m, 1H,
CH‚CH2), 6.88 (s, 1H, oleﬁnic H), 7.27 (t, J1 = 8.0 Hz,
J2 = 8.0 Hz, 1H, H5), 7.38 (d, J= 8.4 Hz, 1H, H7), 7.45 (d,
J= 8.4 Hz, 1H, H70), 7.60 (d, J= 8.4 Hz, 1H, H80), 7.68 (t,
J1 = 8.0 Hz, J2 = 8.0 Hz, 1H, H6), 7.78 (d, J= 8.4 Hz, 1H,
H4), 7.87 (s, 1H, H50), 8.64 (s, 1H, H40);
13C NMR (DMSO-
d6) dC (ppm): 44.97 (allylic NACH2ACH), 109.38, 113.85,
115.51, 117.27, 120.55, 121.34, 123.91, 125.88, 126.71, 129.53,
129.89, 131.07, 132.25, 134.70, 137.32, 138.19, 152.36, 165.44
(18C, Ar-C + oleﬁnic and allylic C‚C), 168.21 (C‚O),
181.69 (C‚O); MS (m/z): 364.9 [M+1]+; Anal. Calcd for C21-
H14ClNO3 (363.79 g/mol): C, 69.33; H, 3.88; N, 3.85; Found:
C, 69.40; H, 4.00; N, 3.61.Please cite this article in press as: Jardosh, H.H., Patel, M.P. Antimicrobia
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ylidene)methyl)quinolin-2(1H)-one (3q)
Yield: 76%; m.p.: 231–233 C; IR (KBr, m, cm1): 3472 (O-H
str.), 3067 (ArC-H str.), 1697, 1601 (C‚O str.); 1H NMR
(DMSO-d6) dH (ppm): 4.96 (d, J= 4.0 Hz, 2H, NACH2A),
5.00 (d, J= 17.2 Hz, 1H, NACH2ACH‚CHtrans), 5.15 (d,
J= 10.4 Hz, 1H, NACH2ACH‚CHcis), 5.93 (m, 1H,
CH‚CH2), 6.72 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 1H, H5),
6.86 (s, 1H, oleﬁnic H), 7.08 (s, 1H, H7), 7.30 (t,
J1 = 7.2 Hz, J2 = 7.6 Hz, 1H, H60) 7.46 (d, J= 8.4 Hz, 1H,
H70), 7.59 (d, J= 8.4 Hz, 1H, H80), 7.63 (d, J= 8.8 Hz, 1H,
H4), 7.92 (d, J= 7.2 Hz, 1H, H50), 8.79 (s, 1H, H40), 11.28 (s,
1H, OH); 13C NMR (DMSO-d6) dC (ppm): 44.98 (allylic
NACH2ACH), 99.40, 103.84, 113.16, 114.04, 115.68, 117.07,
120.57, 123.11, 123.62, 126.61, 130.60, 132.37, 132.78, 139.13,
141.08, 149.41, 167.22, 168.42 (18C, Ar-C + oleﬁnic and
allylic C‚C), 160.48 (C‚O), 181.58 (C‚O); MS (m/z):
345.9 [M+1]+; Anal. Calcd for C21H15NO4 (345.35 g/mol):
C, 73.03; H, 4.38; N, 4.06; Found: C, 72.75; H, 4.30; N, 3.70.
2.4.18. (Z)-1-Allyl-3-((6-hydroxy-3-oxobenzofuran-2(3H)-
ylidene)methyl)-6-methylquinolin-2(1H)-one (3r)
Yield: 78%; m.p.: 245–247 C; IR (KBr, m, cm1): 3448 (O-H
str.), 3067 (ArC-H str.), 1693, 1597 (C‚O str.); 1H NMR
(DMSO-d6) dH (ppm): 2.38 (s, 3H, CH3), 4.98 (d,
J= 4.0 Hz, 2H, NACH2A), 5.02 (d, J= 17.2 Hz, 1H,
NACH2ACH‚CHtrans), 5.17 (d, J= 10.4 Hz, 1H, NACH2-
ACH‚CHcis), 5.94 (m, 1H, CH‚CH2), 6.70 (dd,
J1 = 8.4 Hz, J2 = 1.6 Hz, 1H, H5), 6.82 (s, 1H, oleﬁnic H),
7.01 (s, 1H, H7), 7.21 (d, J= 8.4 Hz, 1H, H70), 7.42 (d,
J= 8.4 Hz, 1H, H80), 7.57 (d, J= 8.4 Hz, 1H, H4), 8.04 (s,
1H, H50), 8.88 (s, 1H, H40), 11.32 (br s, 1H, OH);
13C NMR
(DMSO-d6) dC (ppm): 21.82 (CH3), 44.92 (allylic NACH2-
ACH), 99.44, 103.81, 113.17, 114.08, 115.64, 117.09, 120.51,
123.16, 123.65, 126.63, 130.54, 132.33, 132.75, 139.14, 141.04,
149.43, 167.26, 168.45 (18C, Ar-C + oleﬁnic and allylic
C‚C), 160.43 (C‚O), 181.52 (C‚O); MS (m/z): 360.2
[M+1]+; Anal. Calcd for C22H17NO4 (359.37 g/mol): C,
73.53; H, 4.77; N, 3.90; Found: C, 73.66; H, 4.70; N, 3.65.
2.4.19. (Z)-1-Allyl-3-((6-hydroxy-3-oxobenzofuran-2(3H)-
ylidene)methyl)-6-methoxyquinolin-2(1H)-one (3s)
Yield: 71%; m.p.: 256–258 C; IR (KBr, m, cm1): 3437 (O-H
str.), 3086 (ArC-H str.), 1693, 1616 (C‚O str.); 1H NMR
(DMSO-d6) dH (ppm): 3.77 (s, 3H, OCH3), 4.97 (d,
J= 4.0 Hz, 2H, NACH2A), 5.01 (d, J= 17.2 Hz, 1H,
NACH2ACH‚CHtrans), 5.16 (d, J= 10.4 Hz, 1H, NACH2-
ACH‚CHcis), 5.92 (m, 1H, CH‚CH2), 6.68 (dd,
J1 = 8.4 Hz, J2 = 1.6 Hz, 1H, H5), 6.79 (s, 1H, oleﬁnic H),
6.99 (s, 1H, H7), 7.18 (d, J= 8.4 Hz, 1H, H70), 7.40 (d,
J= 8.4 Hz, 1H, H80), 7.55 (d, J= 8.4 Hz, 1H, H4), 8.01 (s,
1H, H50), 8.82 (s, 1H, H40), 11.29 (br s, 1H, OH);
13C NMR
(DMSO-d6) dC (ppm): 55.81 (OCH3), 44.87 (allylic NACH2-
ACH), 99.41, 103.86, 113.14, 114.12, 115.71, 117.10, 120.56,
123.17, 123.64, 126.61, 130.55, 132.30, 132.72, 139.15, 141.06,
149.42, 167.29, 168.41 (18C, Ar-C + oleﬁnic and allylic
C‚C), 160.48 (C‚O), 181.58 (C‚O); MS (m/z): 376.3
[M+1]+; Anal. Calcd for C22H17NO5 (375.37 g/mol): C,
70.39; H, 4.56; N, 3.73; Found: C, 70.04; H, 4.72; N, 3.64.l and antioxidant evaluation of new quinolone based aurone analogs.
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6 H.H. Jardosh, M.P. Patel2.4.20. (Z)-1-Allyl-6-chloro-3-((6-hydroxy-3-oxobenzofuran-
2(3H)-ylidene)methyl)quinolin-2(1H)-one (3t)
Yield: 73%; m.p.: 259–261 C; IR (KBr, m, cm1): 3448 (O-H
str.), 3067 (ArC-H str.), 1697, 1593 (C‚O str.); 1H NMR
(DMSO-d6) dH (ppm): 4.91 (d, J= 4.0 Hz, 2H, NACH2A),
4.98 (d, J= 17.2 Hz, 1H, NACH2ACH‚CHtrans), 5.01 (d,
J= 10.4 Hz, 1H, NACH2ACH‚CHcis), 5.94 (m, 1H,
CH‚CH2), 6.71 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 1H, H5),
6.81 (s, 1H, oleﬁnic H), 6.99 (s, 1H, H7), 7.22 (d, J= 8.4 Hz,
1H, H70), 7.41 (d, J= 8.4 Hz, 1H, H80), 7.59 (d, J= 8.4 Hz,
1H, H4), 8.02 (s, 1H, H50), 8.90 (s, 1H, H40), 11.39 (br s, 1H,
OH); 13C NMR (DMSO-d6) dC (ppm): 45.15 (allylic NACH2-
ACH), 99.70, 104.51, 112.86, 114.21, 117.16, 118.15, 121.81,
124.83, 126.14, 127.12, 129.10, 131.49, 132.50, 137.69, 139.70,
149.73, 167.44, 168.41 (18C, Ar-C + oleﬁnic and allylic
C‚C), 160.16 (C‚O), 181.41 (C‚O); MS (m/z): 380.6
[M+1]+; Anal. Calcd for C21H14ClNO4 (379.79 g/mol): C,
66.41; H, 3.72; N, 3.69; Found: C, 66.13; H, 3.73; N, 3.91.
2.4.21. (Z)-1-Allyl-3-((4,6-dihydroxy-3-oxobenzofuran-
2(3H)-ylidene)methyl)quinolin-2(1H)-one (3u)
Yield: 65%; m.p.: 241–243 C; IR (KBr, m, cm1): 3441 (O-H
str.), 3082 (ArC-H str.), 1697, 1593 (C‚O str.); 1H NMR
(DMSO-d6) dH (ppm): 4.97 (d, J= 4.0 Hz, 2H, NACH2A),
5.03 (d, J= 17.2 Hz, 1H, NACH2ACH‚CHtrans), 5.16 (d,
J= 10.4 Hz, 1H, NACH2ACH‚CHcis), 5.97 (m, 1H,
CH‚CH2), 6.08 (s, 1H, H5), 6.33 (s, 1H, oleﬁnic H), 6.95 (s,
1H, H7), 7.24 (t, J1 = 7.2 Hz, J2 = 7.6 Hz, 1H, H60) 7.38 (d,
J= 8.4 Hz, 1H, H70), 7.46 (d, J= 8.4 Hz, 1H, H80), 7.72 (d,
J= 7.2 Hz, 1H, H50), 8.68 (s, 1H, H40), 11.09 (br s, 2H, OH);
13C NMR (DMSO-d6) dC (ppm): 45.00 (allylic NACH2ACH),
99.40, 113.09, 114.14, 115.66, 116.94, 120.57, 123.09, 123.59,
125.92, 130.55, 132.26, 132.69, 139.11, 141.15, 149.39, 167.21,
168.40, 169.44 (18C, Ar-C + oleﬁnic and allylic C‚C),
160.49 (C‚O), 181.56 (C‚O); MS (m/z): 362.3 [M+1]+;
Anal. Calcd for C21H15NO5 (361.35 g/mol): C, 69.80; H,
4.18; N, 3.88; Found: C, 69.91; H, 4.35; N, 3.61.
2.4.22. (Z)-1-Allyl-3-((4,6-dihydroxy-3-oxobenzofuran-
2(3H)-ylidene)methyl)-6-methylquinolin-2(1H)-one (3v)
Yield: 62%; m.p.: 257–259 C; IR (KBr, m, cm1): 3410 (O-H
str.), 3082 (ArC-H str.), 1682, 1628 (C‚O str.); 1H NMR
(DMSO-d6) dH (ppm): 2.38 (s, 3H, CH3), 4.94 (d,
J= 4.0 Hz, 2H, NACH2A), 5.00 (d, J= 16.8 Hz, 1H,
NACH2ACH‚CHtrans), 5.16 (d, J= 9.2 Hz, 1H, NACH2-
ACH‚CHcis), 5.94 (m, 1H, CH‚CH2), 6.06 (s, 1H, H5),
6.30 (s, 1H, oleﬁnic H), 6.94 (s, 1H, H7), 7.36 (d, J= 8.4 Hz,
1H, H70), 7.43 (d, J= 8.4 Hz, 1H, H80), 7.69 (s, 1H, H50),
8.64 (s, 1H, H40), 11.02 (br s, 2H, OH);
13C NMR (DMSO-
d6) dC (ppm): 21.78 (CH3), 44.58 (allylic NACH2ACH),
92.82, 96.67, 109.26, 113.90, 120.55, 123.85, 132.20, 133.39,
133.87, 137.03, 139.11, 139.82, 149.62, 149.77, 157.08, 159.03,
168.05, 168.17 (18C, Ar-C + oleﬁnic and allylic C‚C),
160.38 (C‚O), 171.49 (C‚O); MS (m/z): 375.9 [M+1]+;
Anal. Calcd for C22H17NO5 (375.37 g/mol): C, 70.39; H,
4.56; N, 3.73; Found: C, 70.00; H, 4.35; N, 3.76.
2.4.23. (Z)-1-Allyl-3-((4,6-dihydroxy-3-oxobenzofuran-
2(3H)-ylidene)methyl)-6-methoxyquinolin-2(1H)-one (3w)
Yield: 64%; m.p.: 262–264 C; IR (KBr, m, cm1): 3441 (O-H
str.), 3067 (ArC-H str.), 1690, 1624 (C‚O str.); 1H NMRPlease cite this article in press as: Jardosh, H.H., Patel, M.P. Antimicrobia
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J= 4.0 Hz, 2H, NACH2A), 5.01 (d, J= 16.8 Hz, 1H,
NACH2ACH‚CHtrans), 5.14 (d, J= 9.2 Hz, 1H, NACH2-
ACH‚CHcis), 5.95 (m, 1H, CH‚CH2), 6.05 (s, 1H, H5),
6.28 (s, 1H, oleﬁnic H), 6.91 (s, 1H, H7), 7.34 (d, J= 8.4 Hz,
1H, H70), 7.41 (d, J= 8.4 Hz, 1H, H80), 7.68 (s, 1H, H50),
8.62 (s, 1H, H40), 11.01 (br s, 2H, OH);
13C NMR (DMSO-
d6) dC (ppm): 44.49 (allylic NACH2ACH), 55.62 (OCH3),
93.01, 97.13, 109.28, 113.95, 120.56, 123.87, 132.24, 133.41,
133.84, 137.04, 139.16, 139.79, 149.61, 149.73, 157.11, 159.08,
168.12, 168.23 (18C, Ar-C + oleﬁnic and allylic C‚C),
160.42 (C‚O), 172.52 (C‚O); MS (m/z): 392.5 [M+1]+;
Anal. Calcd for C22H17NO6 (391.37 g/mol): C, 67.51; H,
4.38; N, 3.58; Found: C, 67.78; H, 4.44; N, 3.94.
2.4.24. (Z)-1-Allyl-6-chloro-3-((4,6-dihydroxy-3-
oxobenzofuran-2(3H)-ylidene)methyl)quinolin-2(1H)-one
(3x)
Yield: 68%; m.p.: 274–276 C; IR (KBr, m, cm1): 3472 (O-H
str.), 3063 (ArC-H str.), 1692, 1602 (C‚O str.); 1H NMR
(DMSO-d6) dH (ppm): 4.99 (d, J= 4.0 Hz, 2H, NACH2A),
5.08 (d, J= 16.8 Hz, 1H, NACH2ACH‚CHtrans), 5.18 (d,
J= 9.2 Hz, 1H, NACH2ACH‚CHcis), 5.96 (m, 1H,
CH‚CH2), 6.09 (s, 1H, H5), 6.34 (s, 1H, oleﬁnic H), 6.98 (s,
1H, H7), 7.37 (d, J= 8.4 Hz, 1H, H70), 7.45 (d, J= 8.4 Hz,
1H, H80), 7.70 (s, 1H, H50), 8.65 (s, 1H, H40), 11.12 (br s, 2H,
OH); 13C NMR (DMSO-d6) dC (ppm): 44.81 (allylic NACH2-
ACH), 93.52, 97.36, 109.42, 113.98, 120.68, 123.96, 132.44,
133.57, 133.91, 137.21, 139.35, 139.90, 149.56, 149.88, 157.06,
159.13, 168.18, 168.30 (18C, Ar-C + oleﬁnic and allylic
C‚C), 161.22 (C‚O), 172.85 (C‚O); MS (m/z): 396.8
[M+1]+; Anal. Calcd for C21H14ClNO5 (395.79 g/mol): C,
63.73; H, 3.57; N, 3.54; Found: C, 63.74; H, 3.26; N, 3.50.
3. Results and discussion
3.1. Chemistry
The synthetic precursors 2-oxo-1,2-dihydroquinoline-3-carbal-
dehydes 1a–d were synthesized by reﬂuxing respective 2-
chloro-3-formyl quinolines in the presence of 70% acetic acid
and 1-allyl-2-oxo-1,2-dihydroquinoline-3-carbaldehydes 1e–h
were prepared by electrophile favored N-alkylation of 1a–d
in the presence of K2CO3 in DMF at room temperature
(Srivastava and Singh, 2005) (Scheme 1). Precursors 2b and
2c were prepared by reaction of resorcinol/phloroglucinol with
chloroacetonitrile respectively, via a Hoesch acylation to give
an iminium salt and then hydrolyzed under acidic condition
(Shriner and Grosser, 1942; Horning and Reisner, 1948)
(Scheme 1).
The aurones 3a–x were synthesized by condensation of
(Un)substituted benzofuran-3(2H)-one 2a–c with various N-
(Un)substituted quinolone-3-carbaldehyde 1a–h by microwave
irradiation in the presence of 10 mol% NaOH in ethanol at
280 W for 240 s (Scheme 2). This procedure signiﬁcantly short-
ened the reaction time and made it unnecessary to protect the
phenolic hydroxyl groups prior to aldol condensation. Prod-
ucts were obtained in moderate to good yield (61–79%).
The reaction was optimized by varying the mole ratio of
NaOH (Table 1). A mixture of 1a–h and 2a–c was subjected
to microwave irradiation (280 W) by varying mole ratio ofl and antioxidant evaluation of new quinolone based aurone analogs.
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Scheme 1 Synthetic pathway for the synthesis of intermediates 1a–h and 2b,c.
Scheme 2 Representative route for the synthesis of compounds 3a–x.
Quinolone based aurone analogs 7NaOH 2.5, 5.0, 7.5, 10.0 and 12.5 mol%. It was observed that
when the amount of NaOH was increased to 10.0 mol%, the
reaction rate was increased within a shorter reaction time
(240 s). On the other hand, further increase in the amount of
NaOH resulted into the sticky mass which required ice-water
work up and gave poor yield. The formation of products
was continuously checked by thin layer chromatography
(TLC) at regular time interval to optimize the reaction time
and it was found that the reaction was completed within
240 s. The above results showed that the best results were
obtained when the reaction was carried out with 10.0 mol%
of NaOH under microwave irradiation at 280 W for 240 s.
In accordance with the mechanism suggested in the litera-
ture (Lee, 2009), the reaction of the substituted benzofuran-
3(2H)-one 2a–c with N-(Un)substituted quinolone-3-carbalde-
hydes 1a–h proceeded via an aldol condensation. Under the
basic conditions of the reaction, 2a–c forms an enolate whichTable 1 Optimization of catalyst mol% and reaction time for
aldol condensation of 6-chloro-2-oxo-1,2-dihydroquinoline-3-
carbaldehyde and 6-hydroxybenzofuran-3(2H)-one.a
Entry NaOH (mol%) Time (s) Yieldb (%)
1 2.5 540 21
2 5.0 420 34
3 7.5 360 53
4 10.0 240 79
5 12.5 240 61
a Reaction conditions: 6-chloro-2-oxo-1,2-dihydroquinoline-3-
carbaldehyde (3.0 mmol) and 6-hydroxybenzofuran-3(2H)-one
(3.0 mmol), ethanol, MWI, 280 W.
b Isolated yield.
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hyde with loss of water to give the desired aurone (Scheme 3).
The structures of the title compounds 3a–x were conﬁrmed
by FT-IR, 1H NMR, 13C NMR, mass spectra and elemental
analysis. The absorption bands for the title compounds in
IR-spectra were observed in the range of 1593–1697 cm1
which corresponds to two –C‚O group stretching frequencies.
The aromatic C–H stretching bands were observed in the range
of 3063–3086 cm1. The IR spectrum of compounds 3e–l and
3q–x that exhibited a characteristic absorption band in the
range of 3410–3472 cm1 is mainly attributed to the presence
of the OH group. In all cases, a single geometric isomer (Z)
was obtained and conﬁrmed by 1H NMR. It was known from
the literature that the assignment of conﬁguration in aurones
can be possible on the basis of chemical shifts of the oleﬁnic
proton (Huke and Gorlitzer, 1969). It has been well established
that the Z-isomer is thermodynamically more stable than
E-isomer and the chemical shift of the oleﬁnic proton is
deshielded in the E-isomer of aurones and appears downﬁeld
(P7.01 ppm) compared to the Z-isomer (P6.70 ppm)
(Hastings and Heller, 1972; Thakkar and Cushman, 1995;
Beney et al., 2001). The 1H NMR data of the title compounds
3a–x showed that the oleﬁnic proton appeared up ﬁeld around
d 6.28 ppm to d 6.88 ppm. These values indicate that all the
synthesized compounds 3a–x were geometrically pure and
were exclusively cis (Z)-isomers. In the 13C NMR spectral data
of the compounds 3a–x the signals observed at around d
160.16 to d 168.51 are attributed to the carbonyl carbon of
the quinolone ring and signals observed at around d 171.49
to 182.15 are attributed to the carbonyl carbon of the benzof-
uranone ring. The obtained elemental analysis values are in
good agreement with theoretical data. Mass spectra of all the
title compounds gave expected [M+1]+ peak corresponding
to proposed molecular mass.l and antioxidant evaluation of new quinolone based aurone analogs.
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Scheme 3 Conceivable mechanistic pathway for the formation of aurones 3a–x.
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Interestingly, most of the synthesized aurone analogs were
observed to be promising leads and possessing excellent anti-
bacterial and antifungal activities when compared with the
standard drugs (Table 2). Reviewing the antimicrobial activity
data of aurone derivatives 3a–x revealed that, against Gram
positive bacteria Staphylococcus aureus, compound 3w
(MIC = 12.5 lg/mL) was found to exhibit marvelous activity
compared to ampicillin, chloramphenicol and ciproﬂoxacin
while compound 3s (MIC = 50 lg/mL) was as effective as
chloramphenicol and ciproﬂoxacin. Compounds 3k
(MIC = 62.5 lg/mL), 3i (MIC = 100 lg/mL), 3g and 3o
(MIC = 125 lg/mL) as well as 3u (MIC = 200 lg/mL) were
found to be more potent while compounds 3a, 3c, 3f, 3l, 3n,
3q and 3t (MIC = 250 lg/mL) were found to be equipotent
compared to ampicillin. Against Bacillus subtilis, compound
3g (MIC = 25 lg/mL) was found to possess fabulous activity
when compared to all the standard drugs employed. Com-
pound 3w (MIC = 62.5 lg/mL) exhibited signiﬁcant activity
while compounds 3k, 3s and 3v (MIC = 100 lg/mL) exhibited
comparable activity to ampicillin and norﬂoxacin. Against
Clostridium tetani, compound 3i (MIC = 50 lg/mL) was
found to be equally potent with chloramphenicol and norﬂox-
acin. Compounds 3o and 3s (MIC = 62.5 lg/mL) displayed
more efﬁcacy than ampicillin and ciproﬂoxacin. Compounds
3u and 3w (MIC = 100 lg/mL) were found to possess compa-
rable activity with norﬂoxacin. Compounds 3a, 3k and 3v
(MIC = 125 lg/mL) were found to be more potent while com-
pounds 3c, 3d, 3g, 3j, 3l, 3p, 3r and 3t (MIC = 250 lg/mL)
were found to be equipotent when compared with ampicillin.
Against Gram negative bacteria Escherichia coli, com-
pounds 3f and 3v (MIC = 50 lg/mL) showed equal potency
to chloramphenicol. Compounds 3n and 3r
(MIC = 62.5 lg/mL) exhibited excellent activity while com-
pounds 3b, 3t, 3u and 3w (MIC = 100 lg/mL) were found
to be equally potent when compared with ampicillin. Against
Pseudomonas aeruginosa, compound 3v (MIC = 12.5 lg/mL)
was found to possess marvelous activity while compound 3l
(MIC = 25 lg/mL) was found to have similar activity when
compared with ciproﬂoxacin. Against Vibrio cholerae, com-Please cite this article in press as: Jardosh, H.H., Patel, M.P. Antimicrobia
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comparable to all the standard drugs employed except nor-
ﬂoxacin while compound 3j (MIC = 50 lg/mL) displayed
equal activity with chloramphenicol. Compounds 3i and 3v
(MIC = 62.5 lg/mL) showed more potency while com-
pounds 3b, 3l and 3p (MIC = 100 lg/mL) showed equal
potency when compared with ampicillin.
Against fungi Candida albicans, compounds 3d and 3t
(MIC = 100 lg/mL) were found to be equipotent to nystatin.
Compounds 3p (MIC = 125 lg/mL), 3h and 3x
(MIC = 250 lg/mL) were found to be more potent while com-
pounds 3b, 3e, 3g, 3l, 3q and 3w (MIC = 500 lg/mL) were
found to be equipotent when compared with griseofulvin.
Against Aspergillus clavatus, compounds 3d, 3p and 3x
(MIC = 100 lg/mL) exhibited equal potency to nystatin and
griseofulvin.
The investigation of the structure–activity relationship
(SAR) revealed that compounds with an electron donating
group on ring A (R1 = OCH3) gave better results against
Gram positive bacteria e.g., 3g, 3k, 3o, 3s and 3w. Compounds
having an electron donating (R1 = CH3) group showed excel-
lent antibacterial potency against Gram negative bacteria e.g.
3f, 3j, 3h, 3r and 3w. Compounds with an electron withdrawing
group (R1 = Cl) were found to be less potent against any of
the bacterial pathogens except compound 3l, but found to have
signiﬁcant activity against fungal species e.g. 3d, 3h, 3p, 3t and
3x. Compounds having unsubstituted ring A viz., (R1 = H)
were found to be active against S. aureus and C. tetani, e.g.,
3a, 3i and 3u.
Furthermore, compounds having a lipophilic group
(R2 = allyl) in ring B exhibited more potency against a represen-
tative panel of employed species compared to N-unsubstituted
quinolone (R2 = H), e.g., 3n, 3o, 3p, 3r, 3s, 3t, 3u, 3v and 3w.
Compounds containing two OH groups (R3 = R4 = OH) on
ring C showed remarkable inhibition of the growth of
employed pathogens compared to one OH group
(R3 = OH) and unsubstituted ring C (R3 = R4 = H), e.g.,
3i, 3k, 3u, 3v and 3w. From the SAR study of the title deriv-
atives, it is interesting to note that a minor alteration in the
peripheral substitutions present on ring A, B and C may have
a pronounced effect on the antimicrobial activity.l and antioxidant evaluation of new quinolone based aurone analogs.
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Quinolone based aurone analogs 93.3. Antioxidant activity
All the aurone derivatives were evaluated for their antioxidant
activity using the FRAP method (Table 3). Among the com-
pounds tested in this study, compounds 3k and 3u
(R3 = R4 = OH) displayed a relatively high antioxidant power
while compound 3f (R3 = OH, R4 = H) and compounds 3i, 3j,
3l, 3v, 3w and 3x (R3 = R4 = OH) exhibited a better ferric
reducing power. The antioxidant activity of title derivatives
revealed that compounds having two OH groups can easily give
electron for the reduction of Fe+3-TPTZ to Fe+2-TPTZ com-
plex. It is worth to mention that antioxidant activity strongly
depends on the number of hydroxyl group present on ring C.
4. Biological evaluation
4.1. Antimicrobial screening
The in vitro antimicrobial activity of all the compounds and
standard drugs were assessed against three representatives ofTable 2 Antimicrobial activity results of compounds 3a–x.
Compound Minimum Inhibitory
Gram positive bacte
R1 R2 R3 R4 S.A. B.S.
3a H H H H 250 250
3b CH3 H H H 500 200
3c OCH3 H H H 250 125
3d Cl H H H 500 250
3e H H OH H 500 125
3f CH3 H OH H 250 250
3g OCH3 H OH H 125 25
3h Cl H OH H 500 250
3i H H OH OH 100 125
3j CH3 H OH OH 500 250
3k OCH3 H OH OH 62.5 100
3l Cl H OH OH 250 200
3m H Allyl H H 500 250
3n CH3 Allyl H H 250 125
3o OCH3 Allyl H H 125 250
3p Cl Allyl H H 500 500
3q H Allyl OH H 250 250
3r CH3 Allyl OH H 500 200
3s OCH3 Allyl OH H 50 100
3t Cl Allyl OH H 250 200
3u H Allyl OH OH 200 125
3v CH3 Allyl OH OH 500 100
3w OCH3 Allyl OH OH 12.5 62.5
3x Cl Allyl OH OH 500 250
Ampicillin 250 100
Chloramphenicol 50 50
Ciproﬂoxacin 50 50
Norﬂoxacin 10 100
Nystatin n.t. n.t.
Griseofulvin n.t. n.t.
S.A.: Staphylococcus aureus (MTCC 96); B.S.: Bacillus subtilis (MTCC
(MTCC 443); P.A.: Pseudomonas aeruginosa (MTCC 1688); V.C.: Vibrio
Aspergillus clavatus (MTCC 1323).
MTCC: Microbial Type Culture Collection.
n.t.: not tested.
Bold numbers indicate more or equally potent compounds compared to
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(MTCC 441), and C. tetani (MTCC 449); three Gram negative
bacteria E. coli (MTCC 443), P. aeruginosa (MTCC 1688), V.
cholerae (MTCC 3906) and two fungi C. albicans (MTCC 227)
and A. clavatus (MTCC 1323) by the broth microdilution MIC
(Minimum Inhibitory Concentration) method according to the
National Committee for Clinical Laboratory Standards
(NCCLS, 2002). The strains employed for the activity were
procured from (MTCC-Micro Type Culture Collection) the
Institute of Microbial Technology, Chandigarh. Mueller Hin-
ton Broth was used as nutrient medium to grow and dilute
the compound suspension for the test bacteria and Sabouraud
Dextrose Broth was used for fungal nutrition. Ampicillin,
chloramphenicol, ciproﬂoxacin and norﬂoxacin were used as
standard antibacterial drugs, whereas griseofulvin and nystatin
were used as standard antifungal drugs.
Bacterial strains were primarily inoculated into Mueller–
Hinton agar and, after overnight growth, a number of colonies
were directly suspended in saline solution until the turbidity
matched the turbidity of the McFarland standard (approxi-
mately 108 CFU/mL) i.e., inoculum size for test strain wasConcentration (MIC, lg/mL)
ria Gram negative bacteria Fungi
C.T. E.C. P.A. V.C. C.A. A.C.
125 250 500 250 1000 500
500 100 125 100 500 >1000
250 500 250 250 >1000 >1000
250 250 500 125 100 100
500 200 250 200 500 1000
500 50 100 250 1000 500
250 250 250 250 500 >1000
500 125 200 500 250 250
50 125 200 62.5 >1000 500
250 125 62.5 50 >1000 1000
125 250 125 200 1000 1000
250 200 25 100 500 250
500 200 250 250 1000 125
500 62.5 100 250 >1000 250
62.5 125 125 125 1000 500
250 500 125 100 125 100
500 125 200 125 500 500
250 62.5 100 125 1000 >1000
62.5 200 125 200 1000 >1000
250 100 125 250 100 250
100 100 100 20 >1000 1000
125 50 12.5 62.5 1000 >1000
100 100 125 125 500 500
500 200 125 125 250 100
250 100 n.t. 100 n.t. n.t.
50 50 50 50 n.t. n.t.
100 25 25 25 n.t. n.t.
50 10 10 10 n.t. n.t.
n.t. n.t. n.t. n.t. 100 100
n.t. n.t. n.t. n.t. 500 100
441); C.T.: Clostridium tetani (MTCC 449); E.C.: Escherichia coli
cholerae (MTCC 3906); C.A.: Candida albicans (MTCC 227); A.C.:
standard drugs.
l and antioxidant evaluation of new quinolone based aurone analogs.
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Table 3 Antioxidant activity results of compounds 3a–x.
Compd DOD (593 nm) FRAP valuea Compd DOD (593 nm) FRAP valuea
3a 1.162 233.47 3n 0.946 190.07
3b 0.912 183.24 3o 1.098 220.61
3c 1.304 262.01 3p 0.996 200.12
3d 0.992 199.32 3q 1.505 302.39
3e 1.932 388.19 3r 1.610 323.49
3f 2.272 456.51 3s 1.896 380.96
3g 2.221 446.26 3t 1.428 286.92
3h 1.806 362.87 3u 2.138 495.69
3i 2.464 470.37 3v 2.283 458.72
3j 2.291 460.32 3w 2.440 490.26
3k 2.024 495.08 3x 2.312 464.54
3l 2.249 451.88 A.A. 2.476 –
3m 0.779 156.52
A.A. = ascorbic acid.
Concentration of compounds used = 200 lg/mL.
Concentration of standard (A.A.) = 176 lg/mL.
a A.A. mm/100 g sample.
10 H.H. Jardosh, M.P. Pateladjusted to 108 CFU/mL (Colony Forming Unit per milliliter)
well by comparing the turbidity (turbidimetric method). Simi-
larly, fungi were inoculated on Sabouraud Dextrose Broth,
the procedures of inoculum standardization were also similar.
DMSO was used as diluents/vehicle to get the desired concen-
tration of synthesized compounds and standard drugs to test
upon standard microbial strains i.e. the compounds were dis-
solved in DMSO and the solutions were diluted with a culture
medium. Each compound and standard drugs were diluted
obtaining 2000 lg/mL concentration, as a stock solution. By
further progressive dilutions with the test medium, the required
concentrations were obtained for primary and secondary
screening. In primary screening 1000, 500, and 250 lg/mL con-
centrations of the synthesized compounds were taken. The
active compounds found in this primary screening were further
diluted to obtain 200, 125, 100, 62.5 and 50 lg/mL concentra-
tions for secondary screening to test in a second set of dilution
against all microorganisms. Brieﬂy, the control tube containing
no antibiotic is immediately sub cultured [before inoculation] by
spreading a loopful evenly over a quarter of plate of medium
suitable for the growth of the test organism. The tubes are then
put for incubation at 37 C for 24 h for bacteria and 48 h for
fungi. Growth or a lack of growth in the tubes containing the
antimicrobial agent was determined by comparison with the
growth control, indicated by turbidity. The lowest concentra-
tion that completely inhibited visible growth of the organism
was recorded as the minimal inhibitory concentration (MIC,
lg/mL) i.e., the amount of growth from the control tube before
incubation (which represents the original inoculum) is com-
pared. A set of tubes containing only seeded broth and the
solvent controls were maintained under identical conditions so
as to make sure that the solvent had no inﬂuence on strain
growth. The test mixture should contain 108 CFU/mL
organisms. The interpretation of the results was based on
griseofulvin and nystatin breakpoints for fungi and based on
ampicillin, chloramphenicol, ciproﬂoxacin and norﬂoxacin for
bacterial pathogens.Please cite this article in press as: Jardosh, H.H., Patel, M.P. Antimicrobia
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Ferric Reducing Antioxidant Power (FRAP) of newly synthe-
sized compounds was determined chemically using a modiﬁed
FRAP method reported by Benzie and Strain (Benzie and
Strain, 1996). The FRAP method depends upon the reduction
of ferric tripyridyltriazine complex (Fe+3-TPTZ) to the ferrous
tripyridyltriazine (Fe+2-TPTZ) by a reductant (antioxidant) at
a low pH. This ferrous tripyridyltriazine complex has an inten-
sive blue color and can be monitored at 593 nm. The antioxi-
dant potentials of the compounds 3a–x were estimated as their
power to reduce the TPTZ–Fe(III) complex to TPTZ–Fe(II)
complex. The ascorbic acid was used as a standard antioxidant
compound. The results were expressed as ascorbic equivalent
(mmol/100 g compound) and are listed in (Table 2).4.2.1. Reagents
Buffer solution: 0.187 g sodium acetate and 1.6 mL acetic acid
dissolved in double distilled water to make 100 mL.
TPTZ: 0.155 g TPTZ was dissolved in 100 mL 40 mMHCl.
FeCl3 solution: 0.324 g FeCl3 was dissolved in 100 mL dis-
tilled water.
Standard ascorbic acid: 0.176 g standard ascorbic acid was
dissolved in 100 mL distilled water.
Fe(II)–TPTZ(2,4,6-tripyridyl-s-triazine) reagent was pre-
pared by mixing a 10.0 mL TPTZ solution, 10 mL FeCl3 solu-
tion and 100 mL acetate buffer of pH 3.6. A mixture of
200.0 lL sample solution and 3 mL of Fe(II)TPTZ reagent
was incubated at 37 C for 15 min. The absorbance of color
complex Fe(II)TPTZ was measured at 593 nm using ascorbic
acid as standard. The results were expressed as ascorbic equiv-
alent (mmol/100 g compound).
Ascorbic acid taken = 1.99 · 104 mm.
Sample taken = 0.04 mg.
The Ferric Reducing Antioxidant Power (FRAP) can be
calculated using the following equation:l and antioxidant evaluation of new quinolone based aurone analogs.
014.05.014
Quinolone based aurone analogs 11FRAPvalue ðmmA:A:=100gsampleÞ
¼ DOD593 nm ofsample
DOD593 nm ofstandard
 mmofstandard
sampleweight ðmgÞ  10
55. Conclusion
The protocol offers an expeditious synthesis of quinolone
based aurones 3a–x by the use of NaOH-an ecofriendly base.
An adaptation of MAOS approach prevents the side reaction
to occur and facilitate the selectivity in the synthesis of title
compound to afford products in good yield. Reviewing the
antimicrobial and antioxidant activity data, it has been con-
cluded that majority of the compounds were found to be active
against the representative panel of bacterial and fungal patho-
gens and compounds 3k and 3u were found to be the most efﬁ-
cient antioxidants of the series. Also, SAR study indicates that
antimicrobial activity of the title compounds depends on the
nature of peripheral substituents present on ring A, B and C
while antioxidant activity strongly depends on OH groups
present on ring C. Hence, the molecular hybridization of ben-
zofuranone with quinolone nuclei gives the resultant aurone
scaffold with fascinating antioxidant and antimicrobial activ-
ity. It is worth to mention that aurone derivatives bearing
quinolone nucleus can be a vital spot in the medicinal research.
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